Resultados da pesquisa - brain ((tumor rates) or (tumor 1)) treat

Pesquisas alternativas:
tumor rates » tumour rates (Expandir a Pesquisa), tumor rate (Expandir a Pesquisa), tumor states (Expandir a Pesquisa)
tumor 1 » tumor _ (Expandir a Pesquisa), tumor a (Expandir a Pesquisa)

1

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

Por Bidard, François-Clément, Hajage, David, Bachelot, Thomas, Delaloge, Suzette, Brain, Etienne, Campone, Mario, Cottu, Paul, Beuzeboc, Philippe, Rolland, Emilie, Mathiot, Claire, Pierga, Jean-Yves
Publicado em 2012

“... 15-3), CYFRA 21-1), and of serum non-tumor markers (lactate deshydrogenase (LDH), alkaline...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

2

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

Por Curtin, James F, Liu, Naiyou, Candolfi, Marianela, Xiong, Weidong, Assi, Hikmat, Yagiz, Kader, Edwards, Matthew R, Michelsen, Kathrin S, Kroeger, Kurt M, Liu, Chunyan, Muhammad, A. K. M. Ghulam, Clark, Mary C, Arditi, Moshe, Comin-Anduix, Begonya, Ribas, Antoni, Lowenstein, Pedro R, Castro, Maria G
Publicado em 2009

“.... Increased levels of HMGB1 were also detected in the serum of tumor-bearing Ad-Flt3L/Ad-TK (+GCV)-treated...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

3

RBTT-05. TUMOR TREATING FIELDS AND RADIOSURGERY FOR SUPRA- AND/OR INFRATENTORIAL BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS STUDY

RBTT-05. TUMOR TREATING FIELDS AND RADIOSURGERY FOR SUPRA- AND/OR INFRATENTORIAL BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS STUDY

Por P Mehta, Minesh, Gondi, Vinai, Ahluwalia, Manmeet, D Brown, Paul
Publicado no Neuro Oncol (2018)

“...BACKGROUND: Tumor Treating Fields (TTFields) are non-invasive, loco-regional, anti-mitotic...”
Obter o texto integral
Obter o texto integral

Artigo

4

P05.83 Tumor Treating Fields and radiosurgery for supra- and/or infratentorial brain metastases (1–10) from NSCLC in the phase 3 METIS study

P05.83 Tumor Treating Fields and radiosurgery for supra- and/or infratentorial brain metastases (1–10) from NSCLC in the phase 3 METIS study

Por Bähr, O, Mehta, M, Gondi, V, Ahluwalia, M, Brown, P
Publicado no Neuro Oncol (2018)

“...BACKGROUND: Tumor Treating Fields (TTFields) are non-invasive, loco-regional, anti-mitotic...”
Obter o texto integral
Obter o texto integral

Artigo

5

Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery

Palliative Resection of Metastatic Brain Tumors Previously Treated by Stereotactic Radiosurgery

Por Jeon, Yoo Sung, Koh, Young-Cho, Song, Sang Woo, Cho, Joon, Lim, So Dug
Publicado no Brain Tumor Res Treat (2016)

“... of preoperative SRS. METHODS: From 2009 to 2015, 174 patients were treated by SRS for brain metastases, and among...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

6

TRTH-10. PEDIATRIC PHASE 1/1B STUDY OF ENTRECTINIB IN PATIENTS WITH PRIMARY BRAIN TUMORS, NEUROBLASTOMA, AND NTRK, ROS1, OR ALK FUSIONS

TRTH-10. PEDIATRIC PHASE 1/1B STUDY OF ENTRECTINIB IN PATIENTS WITH PRIMARY BRAIN TUMORS, NEUROBLASTOMA, AND NTRK, ROS1, OR ALK FUSIONS

Por Rangaraju, Sunitha, Li, Gang, Christiansen, Jason, Hornby, Zachary, Multani, Pratik, Esquibel, Vanessa, Maneval, Edna Chow
Publicado no Neuro Oncol (2017)

“... brain tumors, neuroblastoma, and other non-neuroblastoma, extracranial solid tumors harboring NTRK, ROS1...”
Obter o texto integral
Obter o texto integral

Artigo

7

PATH-55. THE POTENTIAL ROLE OF ERCC1 AS A BIOMARKER FOR PLATINUM BASED THERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS

PATH-55. THE POTENTIAL ROLE OF ERCC1 AS A BIOMARKER FOR PLATINUM BASED THERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS

Por Kim, Lyndon, Judy, Kevin, Farrell, Christopher, Evans, James, Andrews, David
Publicado no Neuro Oncol (2017)

“... brain tumors is not known. We reviewed a total of 163 patients who had ERCC1 test based on molecular...”
Obter o texto integral
Obter o texto integral

Artigo

8

IMMU-37. VEMURAFENIB ENHANCES THE CYTOTOXICITY OF NY-ESO-1 TCR ENGINEERED T-CELLS FOR BRAF MUTANT BRAIN TUMORS

IMMU-37. VEMURAFENIB ENHANCES THE CYTOTOXICITY OF NY-ESO-1 TCR ENGINEERED T-CELLS FOR BRAF MUTANT BRAIN TUMORS

Por Bethel, Jacob, Aliche, Julian, Orpilla, Joey, Soto, Horacio, Everson, Richard, Davidson, Tom, Wang, Anthony, Liau, Linda, Prins, Robert
Publicado no Neuro Oncol (2018)

“..., and maximal oxygen consumption rate (OCR), whereas T-cells co-cultured with vemurafenib treated tumor cells...”
Obter o texto integral
Obter o texto integral

Artigo

9

Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents

Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents

Por Acharya, Sahaja, Mahmood, Mustafaa, Mullen, Daniel, Yang, Deshan, Tsien, Christina I., Huang, Jiayi, Perkins, Stephanie M., Rich, Keith, Chicoine, Michael, Leuthardt, Eric, Dowling, Joshua, Dunn, Gavin, Keller, Jesse, Robinson, Clifford G., Abraham, Christopher
Publicado no Adv Radiat Oncol (2017)

Assuntos: “...Central Nervous System Tumor...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

10

LGG-12. THE RATE OF GROWTH OF UNTREATED PEDIATRIC BRAIN TUMORS – A CASE SERIES

LGG-12. THE RATE OF GROWTH OF UNTREATED PEDIATRIC BRAIN TUMORS – A CASE SERIES

Por Gilbert, Ariel, Igbaseimokumo, Usiakimi
Publicado no Neuro Oncol (2017)

“... tumors. Given the uniform fatality of malignant brain tumors, no ethical studies of rate of tumor growth...”
Obter o texto integral
Obter o texto integral

Artigo

11

Use of High-Dose Chemotherapy in Front-Line Therapy of Infants Aged Less Than 12 Months Treated for Aggressive Brain Tumors

Use of High-Dose Chemotherapy in Front-Line Therapy of Infants Aged Less Than 12 Months Treated for Aggressive Brain Tumors

Por Milena Guidi, Laura Giunti, Anna Maria Buccoliero, Mariarita Santi, Barbara Spacca, Salvatore De Masi, Lorenzo Genitori, Iacopo Sardi
Publicado em 2020-04-01

Assuntos: “...brain tumor...”
Obter o texto integral

Artigo

12

Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor–induced Behavioral Deficits

Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor–induced Behavioral Deficits

Por King, Gwendalyn D, Kroeger, Kurt M, Bresee, Catherine J, Candolfi, Marianela, Liu, Chunyan, Manalo, Charlene M, Muhammad, AKM Ghulam, Pechnick, Robert N, Lowenstein, Pedro R, Castro, Maria G
Publicado em 2008

“...Glioblastoma multiforme (GBM) is an invasive and aggressive primary brain tumor which is associated...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

13

RT-39 CONTROL OF BRAIN METASTASES FROM RADIORESISTANT TUMORS TREATED BY GAMMA KNIFE RADIOSURGERY

RT-39 CONTROL OF BRAIN METASTASES FROM RADIORESISTANT TUMORS TREATED BY GAMMA KNIFE RADIOSURGERY

Por Yaeh, Andrew, Nanda, Tavish, Rozenblat, Tzlil, Qureshi, Yasir, Saad, Shumaila, Isaacson, Steven, Sisti, Michael, Bruce, Jeffrey, McKhann, Guy, Lassman, Andrew, Jani, Ashish, Wang, Tony
Publicado no Neuro Oncol (2014)

“... histologies. Brain metastases (BM) from these tumors are unlikely to be controlled using the relatively low...”
Obter o texto integral
Obter o texto integral

Artigo

14

P10.05 Periodic assessment with optical coherence tomography in children treated with multimodal therapies for brain tumors

P10.05 Periodic assessment with optical coherence tomography in children treated with multimodal therapies for brain tumors

Por Bacci, G. M., Ghin, M., Lucchesi, M., Guidi, M., Ferraro, M., Farina, S., Favre, C., Genitori, L., Caputo, R., Sardi, I.
Publicado no Neuro Oncol (2016)

Assuntos: “...P10 Pediatric brain tumours...”
Obter o texto integral
Obter o texto integral

Artigo

15

INNV-35. ROUTINE SEQUENCING OF BRAIN TUMORS UNCOVERS HIGH RATES OF ACTIONABLE OPPORTUNITIES: THE UNC EXPERIENCE

INNV-35. ROUTINE SEQUENCING OF BRAIN TUMORS UNCOVERS HIGH RATES OF ACTIONABLE OPPORTUNITIES: THE UNC EXPERIENCE

Por Khagi, Simon, Dees, E Claire, Bell, Emily, Pietrosimone, Kathryn, Garrett, Amy
Publicado no Neuro Oncol (2018)

“...Since November 2017, the University of North Carolina (UNC) Brain Tumor Program has performed next...”
Obter o texto integral
Obter o texto integral

Artigo

16

Frequency, Clinical Correlates, and Ratings of Behavioral Changes in Primary Brain Tumor Patients: A Preliminary Investigation

Frequency, Clinical Correlates, and Ratings of Behavioral Changes in Primary Brain Tumor Patients: A Preliminary Investigation

Por Simpson, Grahame K., Koh, Eng-Siew, Whiting, Diane, Wright, Kylie M., Simpson, Teresa, Firth, Rochelle, Gillett, Lauren, Younan, Kathryn
Publicado no Front Oncol (2015)

“...-diagnosis, with high grade (39%), low grade (22%), or benign tumors (39%). Patients reported frequency rates...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

17

Brain tumors in infants

Brain tumors in infants

Por Ghodsi, Seyyed Mohammad, Habibi, Zohreh, Hanaei, Sara, Moradi, Ehsan, Nejat, Farideh
Publicado no J Pediatr Neurosci (2015)

“... on chemotherapy. CONCLUSION: Brain tumors in infants should be treated with surgical resection, followed...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

18

P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

Por Rangaraju, S., Farago, A., Heym, K. M., Ahn, M., Drilon, A., Potts, S., Hornby, Z., Multani, P., Li, G.
Publicado no Neuro Oncol (2017)

“... brain tumors represent a critical unmet medical need in neuro-oncology. NTRK, ROS1, and ALK gene fusions...”
Obter o texto integral
Obter o texto integral

Artigo

19

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

Por Lee, Eudocia Q., Kuhn, John, Lamborn, Kathleen R., Abrey, Lauren, DeAngelis, Lisa M., Lieberman, Frank, Robins, H. Ian, Chang, Susan M., Yung, W. K. Alfred, Drappatz, Jan, Mehta, Minesh P., Levin, Victor A., Aldape, Kenneth, Dancey, Janet E., Wright, John J., Prados, Michael D., Cloughesy, Timothy F., Gilbert, Mark R., Wen, Patrick Y.
Publicado em 2012

“.... The North American Brain Tumor Consortium examined the safety, pharmacokinetics, and efficacy of combination...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

20

HGG-39. EFFECT OF TUMOR TREATING FIELDS IN CHILDREN WITH RECURRENT OR PROGRESSIVE HIGH-GRADE GLIOMA AND EPENDYMOMA (PEDIATRIC BRAIN TUMOR CONSORTIUM PBTC048)

HGG-39. EFFECT OF TUMOR TREATING FIELDS IN CHILDREN WITH RECURRENT OR PROGRESSIVE HIGH-GRADE GLIOMA AND EPENDYMOMA (PEDIATRIC BRAIN TUMOR CONSORTIUM PBTC048)

Por Goldman, Stewart
Publicado no Neuro Oncol (2018)

“... (OS) of pediatric recurrent/progressive ependymoma is also poor. Tumor Treating Fields (TTFields...”
Obter o texto integral
Obter o texto integral

Artigo

1
2
3
4
5
6
7
8
9
10
11
Seguinte
[29]